ストックスクリーナーアプリを入手
159.20
0.26%
0.42
前日終値:
$158.78
開ける：
$159.45
24時間の取引高:
2.06M
Relative Volume:
0.80
時価総額：
$246.90B
収益：
$60.48B
当期純損益:
$10.40B
株価収益率:
47.81
EPS:
3.3297
ネットキャッシュフロー:
$8.05B
1週間 パフォーマンス:
+1.47%
1か月 パフォーマンス:
+1.44%
6か月 パフォーマンス:
-22.34%
1年 パフォーマンス:
-6.40%
1日の値動き範囲:
$158.53
$160.06
1週間の範囲:
$154.81
$161.29
52週間の値動き範囲:
$153.41
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
159.20 | 246.90B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,179.27 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
261.44 | 630.04B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
276.47 | 488.55B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
145.60 | 359.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.75 | 273.23B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-09-15 | アップグレード | Deutsche Bank | Sell → Hold |
| 2026-09-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-07-13 | ダウングレード | HSBC Securities | Buy → Hold |
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2025-10-27 | 再開されました | Jefferies | Buy |
| 2025-10-16 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2025-04-15 | 開始されました | Exane BNP Paribas | Outperform |
| 2025-02-13 | アップグレード | UBS | Neutral → Buy |
| 2025-02-12 | 開始されました | Morgan Stanley | Overweight |
| 2024-11-20 | アップグレード | UBS | Sell → Neutral |
| 2024-11-06 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-09-13 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-16 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-02-08 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Sell |
| 2024-01-03 | ダウングレード | Jefferies | Buy → Hold |
| 2023-12-18 | 開始されました | HSBC Securities | Buy |
| 2023-09-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-07-12 | アップグレード | UBS | Neutral → Buy |
| 2023-07-05 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-04-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2022-09-15 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | アップグレード | Argus | Hold → Buy |
| 2022-06-14 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-11 | アップグレード | DZ Bank | Sell → Hold |
| 2021-12-07 | ダウングレード | Jefferies | Buy → Hold |
| 2021-08-12 | 再開されました | JP Morgan | Overweight |
| 2021-04-12 | ダウングレード | Argus | Buy → Hold |
| 2021-03-16 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | アップグレード | UBS | Neutral → Buy |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-12-07 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | アップグレード | UBS | Sell → Neutral |
| 2020-11-11 | アップグレード | HSBC Securities | Reduce → Hold |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2019-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-10-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-02 | ダウングレード | UBS | Neutral → Sell |
| 2019-02-05 | 開始されました | Exane BNP Paribas | Outperform |
| 2019-01-25 | アップグレード | Shore Capital | Hold → Buy |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-08-16 | ダウングレード | Jefferies | Buy → Hold |
| 2018-03-19 | アップグレード | Jefferies | Hold → Buy |
| 2018-02-06 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2018-02-05 | 繰り返されました | Bernstein | Outperform |
| 2018-01-18 | 繰り返されました | Leerink Partners | Mkt Perform |
| 2017-12-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2017-10-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | アップグレード | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | アップグレード | Bernstein | Mkt Perform → Outperform |
すべてを表示
Astrazeneca Plc (AZN) 最新ニュース
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
Form 4 ASTRAZENECA PLC For: 8 October By Investing.com - Investing.com UK
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? - Zacks Investment Research
Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? - Zacks Investment Research
AstraZeneca (LSE:AZN) Opened A $1 Billion R&D Center In Kendall Square - Yahoo Finance
Jefferies maintains 'buy' rating on AstraZeneca ahead of third-quarter results - Proactive financial news
AstraZeneca PLC : Buy rating from Berenberg - www.marketscreener.com
US bank expects AstraZeneca to beat third-quarter forecasts as path clears to key lung cancer data - Proactive Investors
AstraZeneca PLC : Jefferies gives a Buy rating - www.marketscreener.com
AstraZeneca PLC : Bernstein reaffirms its Buy rating - www.marketscreener.com
AstraZeneca Takes Drug-Pricing Law Challenge To 4th Circ. - Law360
Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Zacks Investment Research
AstraZeneca’s Real World COPD Study in Russia Signals Strategic Respiratory Focus - TipRanks
AstraZeneca advances Tuesday, outperforms market - MarketWatch
Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? - Zacks Investment Research
Citi raises AstraZeneca target to £186 as tozorakimab prospects improve - Proactive financial news
AstraZeneca opens new R&D centre in Cambridge, US - Pharmaceutical Technology
AstraZeneca Invests Over $1bn in Massachusetts - marketscreener.com
AstraZeneca Launches Research, Development Center in US - marketscreener.com
‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans - The Business Journals
AstraZeneca CEO Soriot says drugmaker can grow without big acquisition - Seeking Alpha
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment - CNBC
AstraZeneca to invest over $1 billion in Massachusetts, boost workforce - marketscreener.com
AstraZeneca to invest over $1B in Massachusetts ops - Breakingthenews.net
A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan
AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts - Financial Times
AstraZeneca PLC (ZEG.DE) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Summit Therapeutics Closes $2 Billion AstraZeneca Investment - grafa.com
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - TradingView
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos - Zacks Investment Research
FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting - Zacks Investment Research
AstraZeneca completes USD2 billion Summit investment - marketscreener.com
Cancer-drug partnerships accompany AstraZeneca (AZN)'s completed investment in Summit. - Stock Titan
AstraZeneca Finalizes $2 Billion Investment in Summit Therapeutics - marketscreener.com
AstraZeneca has put $2 billion into Summit to support work on an experimental cancer treatment. - Stock Titan
REGAstraZeneca PLCAstraZeneca completes equity investment in Summit - TradingView
AstraZeneca completes equity investment in Summit Therapeutics - AstraZeneca
AstraZeneca PLC (ZEG.SG) stock price, news, quote and history - Yahoo Finance Australia
AstraZeneca PLC, Daiichi Sankyo And Summit Therapeutics Inc. Announce Clinical Collaboration To Evaluate Datroway In Combination With Ivonescimab Across Multiple Tumour Types - marketscreener.com
Summit Deal Could Help Futureproof AstraZeneca’s Datroway - insights.citeline.com
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact - Pharmaceutical Technology
AstraZeneca, Daiichi Sankyo Expand Cancer Push Through Summit Partnership - benzinga.com
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies - Zacks Investment Research
Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’ - Yahoo Finance
Lung and breast cancers are targets of AstraZeneca (AZN)'s new three-company trial collaboration. - Stock Titan
Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity - GlobeNewswire Inc.
AstraZeneca, Daiichi Partner With Summit on Cancer-Drug Trials - Bloomberg.com
AstraZeneca and two partners plan to test a cancer-drug pairing in breast cancer - Stock Titan
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo collaborate with Summit Therapeutics to evaluate Datroway-ivonescimab combo - Seeking Alpha
Astrazeneca Plc (AZN) 財務データ
収益
当期純利益
現金流量
EPS
Astrazeneca Plc (AZN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sharma Mani | See Remarks |
May 20 '26 |
Sale |
185.78 |
11,893 |
2,209,482 |
19,262 |
1.82%
大文字化:
|
ボリューム (24 時間):